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Prostate cancer (PCa) is one of the main leading causes of cancer-related mortality and the most frequently 
diagnosed cancer in  men1. he conventional therapy for early stage PCa includes surgical removal of the prostate 
and hormonal ablation by androgen deprivation therapy (ADT), which is efective in many  cases2,3. However, 
these therapies oten fail due to an incomplete depletion of tumor cells, resulting in tumor relapse and in patients 
developing castration-resistant PCa (CRPC), for which there are currently few therapeutic  options4,5.
here is increasing evidence that most human cancers are driven by a rare population of transformed cells 
with stem and progenitor properties, deined as cancer stem cells (CSCs)6,7. CSCs represent a small subpopula-
tion of largely quiescent cells that reside within tumors and have the potential to diferentiate into recognizable, 
replicating tumor cells; therefore they are considered major elements in tumor initiation, growth and progres-
sion, metastasis and tumor  heterogeneity8,9. Accumulating evidence indicates that PCa CSCs are characterized 
by the expression of speciic cell surface markers, including CD133 and CD44, and are less diferentiated than 
transient-amplifying (TA) or committed-basal (CB)  cells10–12. hese CSCs are able to self-renew and show high 
clonogenic ability, which makes them key drivers in the oncogenic and metastatic  process13,14. Due to their 
resistance to conventional therapies, CSCs are related to tumor recurrence ater chemo- and radiotherapy: for 
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this reason, targeting CSCs has been suggested as a potential novel therapy to suppress PCa  metastasis15,16. Gene 
expression proiling of PCa CSCs from primary cultures revealed a signiicant role for signal transducer and 
activator of transcription 3 (STAT3) in regulating the stem cell niche, indicating that STAT3 inhibition could be 
a valid strategy to selectively target PCa-CSC11,17–19.
Our group has previously characterized galiellalactone (GL) as a direct STAT3 inhibitor that binds to STAT3 
to prevent the transcription of its target genes without interfering with its upstream  activation20. Blockade of 
STAT3 by GL not only reduces proliferation and induces apoptosis of PCa cells and ALDH1A1 expressing cells 
in vitro, it also inhibits the growth of prostate tumors and the metastatic spread to regional and distal lymph 
nodes in vivo21,22. In this study we investigated the efect of GL on PCa CSCs in several models, including 
patient-derived primary tumor cultures and docetaxel resistant PCa cell spheres, in order to better characterize 
this compound as a therapeutic approach for PCa patients.
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irst determined the characteristics of stem and non-stem cell populations in DU145 cells, based on the expres-
sion of stem (CD133), basal (CD44) and luminal (CD24) cell surface markers. Flow cytometry analysis showed 
that CSCs  (CD133+/CD44+) were detected as a small population in DU145 cells (1,044%), while the most abun-
dant population (85.74%) was represented by TA/CB cells  (CD44+/CD24+) (Fig. 1a). We then sorted CSCs and 
TA/CB populations based on the expression of the same surface markers and sought to determine their char-
Figure 1.  Characterization of stem cell and transient amplifying/committed basal cell populations from DU145 
cells. (a) Flow cytometry analysis of CSCs  (CD133+CD44+) and TA/CB  (CD44+CD24+) populations in DU145 
cells. (b) qPCR analysis of CD133, CD44 and ALDH1A1 gene expression in CSCs and TA/CB cells sorted from 
DU145 cells. Results represent the mean ± s.e.m. of ive independent experiments (n = 5), each performed in 
triplicate. *p < 0.05; **p < 0.01. (c) Colony formation assay of CSCs and TA/CB cells sorted from DU145 cells and 
grown on collagen-coated plates. Representative images are shown on the let; the number of colonies is shown 
in the right graph. Results represent the mean ± s.e.m of three (n = 3) independent experiments, each performed 
in duplicate. (d) Sphere formation assay on CSCs and TA/CB cells sorted from DU145 cells. Representative 
images are shown on the let; the number of spheres is shown in the right graph. Results represent the 
mean ± s.e.m of three (n = 3) independent experiments, each performed in triplicate. (e) Gene expression 
analysis of stemness related genes in spheres derived from CSCs  (CD133+/CD44+) and TA/CB  (CD44+/CD24+) 
populations. Gene expression was studied by qPCR for CD133, CD44 and ALDH1A1. Results represent the 
mean ± s.e.m of three (n = 5) independent experiments, each performed in triplicate. *p < 0.05; **p < 0.01. (f) 
Gene expression analysis of STAT3-target genes in spheres derived from CSCs  (CD133+/CD44+) and TA/CB 
 (CD44+/CD24+) populations. Gene expression was studied by qPCR for c-myc, Bcl-XL, Mcl-1 and Survivin. 
Results represent the mean ± s.e.m of three (n = 3) independent experiments, each performed in triplicate. 
*p < 0.05. (g) Immunocytochemical analysis of phosphorylated STAT3 (pSTAT3) levels in DU145 cells (panel I), 
CSCs (panel II) and TA/CB cells (panel III) sorted from DU145 cells. LNCaP cells treated with 50 ng/ml IL-6 
were used as positive control (panel IV). Panels V to VIII represents enlargements of the area in the red square. 
Arrows in (VII) indicate positive cytoplasmic staining. Scale bar = 100 μm.
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acteristics. Sorted CSCs showed higher expression levels of the stemness genes CD133, CD44 and ALDH1A1, 
compared to TA/CB cells (Fig. 1b). Furthermore, we found that cells from both populations were able to form 
colonies (Fig. 1c) and spheres (Fig. 1d) when grown in vitro. Notably, spheres derived from CSCs  (CD133+/
CD44+) showed higher expression of CD133, CD44 and ALDH1A1 (Fig.  1e) as well as higher levels of the 
STAT3-target genes c-myc, Bcl-XL, Mcl-1 and Survivin compared to spheres derived from TA/CB cells  (CD44
+/
CD24+) (Fig. 1f). Furthermore, immunocytochemistry analysis on sorted cells from DU145 showed that CSCs 
express higher levels of active phosphorylated STAT3 (pSTAT3) compared to the TA/CB population (Fig. 1g). 
Altogether, these data indicate that  CD133+/CD44+ cells and their derived spheres retain stemness characteris-
tics and show high activity of STAT3, in agreement with previously published  work11,21.
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Ǥ We next determined the efect of STAT3 
inhibition by GL on CSCs and TA/CB cell populations derived from DU145 cells. he treatment with GL sig-
niicantly compromised the viability of both DU145-CSCs and -TA/CB cells at 24 h and 48 h in a concentration-
dependent manner, indicating that both cell populations’ viability depends on STAT3 (Fig. 2a). Since it is known 
that prostate CSCs are dependent on the JAK-STAT3 signaling pathway for their survival and  proliferation17, 
we next sought to determine the potential of GL to disrupt their ability to form colonies and spheres. We per-
formed colony- and sphere-formation assays in the presence of GL on  CD133+ (CSCs) and  CD133− (TA/CB) 
cells isolated from DU145 cells. We found that GL signiicantly reduced the number of CSCs- and TA/CB-
derived colonies in a concentration-dependent manner: however, CSCs were slightly more sensitive to lower 
concentrations of GL than TA/CB cells, as their colony-forming ability signiicantly decreased by almost 50% in 
the presence of 2.5 µM GL ater 24 h (Fig. 2b). he same level of colony-forming inhibition was reached in TA/
CB cells only in the presence of 10 µM GL ater 24 h or 2.5 and 5 µM GL ater 48 h, indicating that this population 
Figure 2.  Efect of GL on the viability, colony and sphere formation ability of CSCs and TA/CB cells. (a) 
Viability assay on CSCs and TA/CB cells sorted from DU145 cells and treated with vehicle or 2.5–10 μM GL 
for 24 or 48 h. Results represent the mean ± s.e.m of six (n = 6) independent experiments, each performed 
in triplicate. Statistical signiicance was determined using one-way ANOVA with Bonferroni post hoc test. 
*p < 0.05; ***p < 0.001. (b) Colony formation assay of CSCs  (CD133+, top) and TA/CB  (CD133−, bottom) cells 
sorted from DU145 cells and grown on collagen-coated plates for 24 or 48 h in the presence of vehicle or 
2.5–10 μM GL. Representative images are shown on the let; the number of colonies is shown in the right graph. 
Results represent the mean ± s.e.m of three (n = 3) independent experiments, each performed in triplicate. 
Statistical signiicance was determined using one-way ANOVA with Bonferroni post hoc test. *p < 0.05; 
**p < 0.01; ***p < 0.001; n.s. not signiicant. (c) Sphere formation assay on CSCs cells sorted from DU145 
cells and grown in the presence of vehicle or 2.5–10 μM GL. Representative images are shown on the let; the 
number of CSCs-derived spheres is shown in the right graph. Results represent the mean ± s.e.m of three (n = 3) 
independent experiments, each performed in triplicate. Statistical signiicance was determined using one-way 
ANOVA with Bonferroni post hoc test. ***p < 0.001. (d) Sphere formation assay on TA/CB cells sorted from 
DU145 cells and grown in the presence of vehicle or 2.5–10 μM GL. Representative images are shown on the 
let; the number of CSCs-derived spheres is shown in the right graph. Results represent the mean ± s.e.m of three 
(n = 3) independent experiments, each performed in triplicate. Statistical signiicance was determined using one-
way ANOVA with Bonferroni post hoc test. **p < 0.01; n.s. not signiicant.
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is slightly more resistant (Fig. 2b). Similarly, GL signiicant reduction of the number of CSCs-derived spheres 
was also concentration-dependent (Fig. 2c), while the number of TA/CB-derived spheres was reduced only in 
the presence of higher concentrations of GL (10 µM) (Fig. 2d). Of note, mRNA expression analysis showed that 
the STAT3-regulated genes Mcl-1, Bcl-XL, c-myc and survivin were signiicantly down-regulated in CSC-derived 
spheres treated with GL, supporting the hypothesis that the STAT3 signaling is involved in survival of PCa-CSCs 
(Fig. 3a). he expression of Mcl-1 and Bcl-XL in TA/CB-derived spheres was signiicantly decreased only ater 
treatment with 10 µM GL and no efect of GL was observed on c-myc or survivin expression (Fig. 3b), likely 
relecting the lower expression of pSTAT3 in TA/CB cells compared to CSCs. We next explored the efects of 
GL in vivo on the expression of stem cell markers in PCa xenograts in two mouse models that we previously 
 described22,23. In the irst approach, nude mice were injected orthotopically with DU145-Luc cells and treated 
with GL or vehicle for 9 weeks22. Our IHC analysis of the primary tumors showed that the treatment with GL 
reduced the expression of the stemness marker CD44 by 40% (Fig. 4a). Furthermore, we found that the expres-
sion levels of the stemness marker ALDH1A1 were also decreased in tumors treated with GL compared to 
vehicle-treated samples (Fig. 4b). he treatment with GL did not afect the mRNA levels of STAT3 (Fig. 4c), nor 
its protein levels and the phosphorylation of STAT3 on Tyrosine-705 (Y705) and Serine-727 (S727) (Fig. 4d), 
but it signiicantly decreased the expression levels of the STAT3-target genes Mcl-1 and Bcl-XL (Fig. 4e-f). hese 
results are in agreement with previous data showing that GL inhibits STAT3 binding to DNA without afecting 
its phosphorylation  status20. In the second in  vivo approach, DU145 cells were injected subcutaneously and 
animals subjected to daily intraperitoneal injections of GL or vehicle for 3 weeks23. In this model, IHC analy-
sis of the primary tumors showed that the treatment with GL reduced the expression of the stemness marker 
ALDH1A1 by 50% (Fig. 4g). Interestingly, previous data from our group showed that the treatment with GL in 
this model also reduced the mRNA expression levels of ALDH1A1 and of the STAT3-target genes Mcl-1 and 
Bcl-XL
21,23. Taken together, these data indicate that treatment with GL reduces the viability, the colony forming 
and the sphere-forming eiciency of DU145-CSCs in vitro, and reduces the expression of stemness markers and 
STAT3-regulated genes in vivo.  
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Ǥ We next investigated the efect of GL on spheres derived from docetaxel-
resistant DU145 cells (DU145-DR) and on spheres derived from three treatment-naïve patients with diferent 
Gleason scores, obtained ater radical prostatectomy or prostate biopsy at diagnosis (Table  1). As shown in 
Fig. 5, DU145-DR- and patient-derived spheres were highly enriched in two or more stemness genes compared 
to the parental cells (Fig. 5a,b,d,f,h), which indicates that these spheres retain stemness characteristics and is 
consistent with their ability to survive and proliferate in a selective medium without adhering to a solid surface. 
Interestingly, DU145-DR spheres showed a signiicant enrichment in stemness genes also compared to spheres 
derived from docetaxel-sensitive cells (DU145-DS), which corroborates the role of these genes in drug resist-
ance (Fig. 5b). We also detected higher levels of STAT3 expression in both DU145-DS and DU145-DR derived 
spheres compared to the adherent controls (Suppl. Fig. S1). Of note, the expression of STAT3 decreased in GL 
treated spheres, which conirms the role of STAT3 in driving sphere formation and stemness features (Suppl. 
Fig. S1). Both DU145-DR and patients-derived spheres also showed a slower growth rate (Suppl. Fig. S2a-c-e) 
and a greatly reduced protein synthesis activity (Suppl. Fig. S2b-d-f) compared to the parental cells, in agree-
ment with their CSC phenotype. he viability of DU145-DR spheres was signiicantly compromised by GL in a 
concentration-dependent manner, reaching a 50% reduction ater treatment with 10 µM GL (Fig. 5c). Spheres 
derived from patients #143, #318 and #285 responded strongly to GL already at 2–5 µM, showing a signiicant 
decrease in viability up to 60%, 40% and 70%, respectively, at 8–10 µM GL (Fig. 5e,g,i). In both DU145-DR 
and patient-derived spheres, we did not detect any diference between spheres and parental cells in terms of 
viability ater the treatment with GL (data not shown). However, while both DU145-DR spheres and parental 
cells were sensitive to GL, we found that DU145-DR spheres were more sensitive to GL than DU145-DS spheres 
 (IC50 = 6.2 μM and  IC50 = 10.1 μM, respectively) (Table 2).  
Taken together, these data indicate that targeting STAT3 with GL signiicantly reduces the viability of doc-
etaxel-resistant and patient-derived spheres with stemness characteristics.
Figure 3.  Efect of GL on the expression of STAT3-target genes. (a, b) qPCR analysis of Mcl-1, Bcl-XL, c-myc 
and survivin gene expression in CSCs-derived spheres (a) and in TA/CB-derived spheres (b) grown in the 
presence of vehicle or 2.5–10 μM GL. Results represent the mean ± s.e.m. of three independent experiments 
(n = 3), each of which was performed in triplicate. *p < 0.05; **p < 0.01; ***p < 0.001.
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In this study we demonstrate that inhibition of activated STAT3 by GL can decrease the viability of docetaxel-
resistant and patient-derived spheres retaining stemness characteristics, indicating that this is a promising 
approach to target the cancer stem cell niche in PCa. he prostate CSCs were identiied based on the expression 
of CD133 and CD44 cell surface markers  (CD133+/CD44+), which allowed us to distinguish CSCs from the 
more diferentiated transient-amplifying (TA) or committed-basal (CB) non-stem cell populations  (CD44+/
Figure 4.  Efect of GL on the expression of STAT3-target genes and on the expression of stemness genes 
in vivo. (a) Representative images and number of  CD44+ cells in DU145-luc orthotopic xenograt from vehicle- 
and GL-treated mice. Results are presented as the mean ± s.e.m; statistical signiicance was determined using 
an unpaired Student t test. *p < 0.05. All images were taken with a 20 T objective (scale bar = 100 mm). (b) 
qPCR analysis of ALDHA1 levels in tumor samples of mice injected orthotopically with DU145-luc cells and 
treated vehicle- or GL-treated. Results represent the mean ± s.d. of three independent experiments (n = 3), 
each performed in triplicate. *p < 0.05. (c) qPCR analysis of STAT3 levels in tumor samples of mice injected 
orthotopically with DU145-luc cells and treated with vehicle or GL. Results represent the mean ± s.d. of three 
independent experiments (n = 3), each performed in triplicate. (d) Western blot analysis of pSTAT3-Y705, 
pSTAT3-S727 and total STAT3 levels in tumor samples of mice injected orthotopically with DU145-luc cells 
and treated with vehicle or GL. Lysates from DU145 and LnCaP cell lines were used as positive and negative 
controls, respectively. A representative blot of two independent experiments (n = 2) is shown. (e) qPCR analysis 
of Mcl-1 levels in tumor samples of mice injected orthotopically with DU145-luc cells and treated with vehicle 
or GL. Results represent the mean ± s.d. of three independent experiments (n = 3), each performed in triplicate. 
*p < 0.05. (f) qPCR analysis of Bcl-XL levels in tumor samples of mice injected orthotopically with DU145-luc 
cells and treated with vehicle or GL. Results represent the mean ± s.d. of three independent experiments (n = 3), 
each performed in triplicate. *p < 0.05. (g) Representative images and number of  ALDH1A1+ cells in DU145 sub 
cutaneous xenograts from vehicle- and GL-treated mice. Results are presented as the mean ± s.e.m; statistical 
signiicance was determined using an unpaired Student t test. **p < 0.01. All images were taken with a 20 T 
objective (scale bar = 100 mm).
Table 1.  he table summarizes the age, PSA level, Gleason Score and metastasis status of the patients that 
participated in the study. Patients samples were obtained ater radical prostatectomy or prostate biopsy at 
diagnosis and used to generate prostate spheres for further studies.
Patient information
Patient # Age PSA Gleason score Metastasis
143 78 1606 5 + 4 Positive
285 65 6.16 3 + 4 Unknown
318 67 5 4 + 5 Unknown
6Vol:.(1234567890)
SCIENTIFIC REPORTS |        (2020) 10:13958  | ǣȀȀǤȀͷͶǤͷͶ͹;ȀͺͷͻͿ;ǦͶ͸ͶǦͽͶͿͺ;Ǧͻ
www.nature.com/scientificreports/
Figure 5.  Efect of GL on docetaxel-resistant DU145 spheres and on patient-derived spheres. (a) qPCR 
analysis of stemness related genes in DU145-DR adherent cells and spheres. Results represent the mean ± s.d. 
of three independent experiments (n = 3), each performed in triplicate. ***p < 0.001; n.s. not signiicant. (b) 
qPCR analysis of stemness related genes in DU145-DR spheres and DU145-DS spheres. Results represent the 
mean ± s.d. of three independent experiments (n = 3), each performed in sextuplicate. **p < 0.01; ***p < 0.001; 
n.s. not signiicant. (c) Viability assay on spheres derived from DU145-DR cells grown in the presence of 
vehicle or 2.5–10 μM GL for 48 h. Results represent the mean ± s.d. of six (n = 6) independent experiments, each 
performed in quintuplicate. Statistical signiicance was determined using one-way ANOVA with Bonferroni 
post hoc test. ***p < 0.001. (d) qPCR analysis of stemness related gene expressions in spheres and adherent cells 
derived from primary tumor #143. Results represent the mean ± s.d. of six independent experiments (n = 6), 
each performed in triplicate. *p < 0.05; **p < 0.01; n.s. not signiicant. (e) Viability assay on spheres derived from 
primary tumor #143 grown in the presence of vehicle or 2.5–10 μM GL. Results represent the mean ± s.d. of 
seven (n = 7) independent experiments, each performed in quintuplicate. Statistical signiicance was determined 
using one-way ANOVA with Bonferroni post hoc test. ***p < 0.001. (f) qPCR analysis of stemness related gene 
expressions in spheres and adherent cells derived from primary tumor #318. Results represent the mean ± s.d. 
of six independent experiments (n = 6), each performed in triplicate. *p < 0.05; **p < 0.01; n.s. not signiicant. 
(g) Viability assay on spheres derived from primary tumor #318 grown in the presence of vehicle or 2.5–10 μM 
GL. Results represent the mean ± s.d. of ten (n = 10) independent experiments, each performed in quintuplicate. 
Statistical signiicance was determined using one-way ANOVA with Bonferroni post hoc test. ***p < 0.001. (h) 
qPCR analysis of stemness related gene expressions in spheres and adherent cells derived from primary tumor 
#285. Results represent the mean ± s.d. of six independent experiments (n = 6), each performed in triplicate. 
*p < 0.05; **p < 0.01; n.s. not signiicant. (i) Viability assay on spheres derived from primary tumor #285 grown in 
the presence of vehicle or 2–8 μM GL. Results represent the mean ± s.d. of six (n = 6) independent experiments, 
each performed in quintuplicate. Statistical signiicance was determined using one-way ANOVA with 
Bonferroni post hoc test. ***p < 0.001.
Table 2.  IC50 of GL in DU145-DS adherent cells, DU145-DS spheres, DU145-DR adherent cells and 
DU145-DR spheres. DU145-DR spheres and parental cells were sensitive to GL. However, DU145-DR spheres 
were more sensitive to GL than DU145-DS spheres  [IC50 = 6.2 μM and  IC50 = 10.1 μM, respectively; p < 0.05 
(*)].
GL  IC50 (μM)
DU145-DS adherent cells 8.51
DU145-DS spheres 10.1
DU145-DR adherent cells 6.24
DU145-DR spheres 6.21
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CD24+)10–12. he expression of CD133 and CD44 on the cell surface is considered a marker of stemness in several 
cancer types, including prostate, as these proteins are involved in cell–cell interactions, cell adhesion and migra-
tion of tumor  cells24,25. Previous studies have reported that  CD44+ PCa cells from xenograted human tumors are 
enriched in tumorigenic and metastatic progenitor  cells26, while  CD133+ cells have elevated proliferative potential 
in vitro and the ability to form prostatic-like acini in immunocompromised  mice27. Additionally, other studies 
have shown that  CD133+/CD44+ cells display in vitro self-renewal and express core stem cell  genes28–30. Here 
we show that CSCs sorted from DU145 cells express high levels of stem cell genes and can form colonies and 
spheres in vitro: thus, our results are in agreement with previous studies and our model conirms that  CD133+/
CD44+ cells retain stemness features. However, our analysis on spheres derived from docetaxel-resistant DU145 
cells (DU145-DR) and spheres derived from PCa patients show that the expression of some stem cell markers is 
increased, while the expression of some others is unchanged. his relects the high level of heterogeneity oten 
described in the  clinic31,32. Nevertheless, our spheres express high levels of several pluripotency genes, includ-
ing NANOG, ALDH1A1, SOX2, OCT4 and KLF4, among others. Several studies have validated the implication 
of these genes in the regulation of the PCa stem cell niche, which conirms that these spheres retain stemness 
 characteristics33–37. Indeed, our data indicate that a pattern of diferent embryonic pluripotency genes is crucial 
for the identiication of docetaxel-resistant prostate CSCs. Additionally, we show that the PCa CSCs express high 
levels of active phosphorylated STAT3 (pSTAT3), and that GL down-regulates transcriptional targets of STAT3 in 
these cells compared to TA/CB non-stem cell populations, indicating STAT3 activity in CSCs. Other groups have 
demonstrated that the JAK-STAT signaling pathway is constitutively active in the PCa stem-like population and 
that stem-like and progenitor cells from human PCa patients have constitutively activated  STAT311,38,39. Further-
more, gene expression proiling analyses have reported the importance of the JAK-STAT pathway in regulating 
the stem cell niche in  PCa17. hus, in agreement with previously published work, prostate CSCs are dependent 
on STAT3 signaling, conirming the importance of this pathway for the survival of stem-like cells in PCa.
he current therapeutic strategies for PCa emphasize the elimination of the bulk of the cells within the tumor, 
which oten leads to therapy resistance and activation of normally quiescent CSCs, in turn repopulating the tumor 
and ultimately promoting disease  progression24,40. herefore, developing therapeutics that can selectively target 
CSCs along with the more diferentiated cancer cells is of fundamental importance and represents one of the 
current challenges in PCa therapy. In this study we demonstrate that inhibition of STAT3 by GL can signiicantly 
decrease the viability of CSCs in multiple diferent models, including docetaxel-resistant and patient-derived 
spheres. Notably, we found that Docetaxel-resistant spheres were more sensitive to GL than Docetaxel-sensitive 
spheres  (IC50 = 6.2 μM and  IC50 = 10.1 μM, respectively). his could be because the resistant spheres are the result 
of a selection of cells surviving to the toxic drug treatment (Docetaxel, in this case) and as a consequence these 
cells are not able to survive to a further challenge with GL. In contrast, the sensitive spheres have not undergone a 
drug selection treatment and therefore they likely maintain diverse cell subpopulations that may be able to resist 
to GL. hus, we provide evidence that GL can target both CSCs and non-CSCs populations, emphasizing the 
relevance of such an approach for a more efective  treatment19,21. STAT3 has been demonstrated to contribute to 
the development of resistance to the anti-androgen enzalutamide and STAT3 inhibition by GL can enhance the 
efect of anti-androgen therapy as well as decrease proliferation of resistant PCa  cells41. his study now expands 
on the potential therapeutic beneits of this small molecule by showing that GL can harness the main bulk of 
tumor cells as well as the tumor-initiating stem cell niche in which activation of STAT3 is clearly demonstrated. 
Notably, the fact that DU145-DR spheres are sensitive to GL suggests that GL is a potential drug to be used in 
combination with a second line therapy for PCa treatment. Moreover, targeting the downstream activity of STAT3 
with this approach could be highly beneicial because it would reduce the risks of developing therapy resistance 
to upstream inhibitors, thus decreasing side efects and increasing eicacy of the therapy.
Taken together, our data conirm that PCa-CSCs are dependent on STAT3 signaling for survival, and that 
blocking this pathway with GL efectively impairs their viability. Our indings here provide the irst evidence 
that GL can target the CSCs in patient-derived primary prostate tumor cultures. We propose that the STAT3 
inhibitor GL acts by reducing the viability of PCa-therapy-resistant cells in both CSCs and non-CSC populations.

All experimental procedures and protocols were approved by the Regional Ethical Board at Lund University 
(Sweden), the Ethic Commitee of Clinic Investigation at the Vall d’Hebron Hospital of Barcelona (Spain) and 
the Committee of Bioethics of the Faculty of Medicine at the Clinical Hospital of the University of Chile (Chile). 
All experiments were performed in accordance with relevant guidelines and regulations.
ǡǤ DU145 and LNCaP cells were from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA) and were cultured in RPMI-1640 medium supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin. DU145-Luciferase (DU145-Luc) were from Anthem 
Biosciences (Bangalore, India) and were grown in Dulbecco’s Modiied Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells were regularly tested to conirm the 
absence of Mycoplasma infection. he molecular characterization of the cell lines was performed by LGC Stand-
ards (Cologne, Germany) and the results were then evaluated by comparison with the ATCC database (https ://
www.lgcst andar ds-atcc.org/STR_Datab ase.aspx). Our batches of cells revealed 100% match to the ATCC stand-
ard. Docetaxel-resistant DU145 (DU145-DR) cells were developed as previously  described42,43. DU145-DR cells 
were cultured in RPMI-1640 (BioWest) supplemented with 10% FBS, 2  mM l-glutamine, 100  U of penicil-
lin/ml, 100 μg/ml of streptomycin and 0.1 mM non-essential amino acids (all from BioWest) in the presence 
of 2.5 nM of docetaxel (Sigma-Aldrich, St. Louis, MO). Primary cell lines were isolated from human prostate 
cancer samples. Informed consent͒ was obtained from all patients involved in the study and all methods were 
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carried out in accordance with relevant guidelines and regulation of the local ethics committees that approved 
the study. he prostate cancer tissue #143 was obtained from a patient biopsy with Gleason Score 9 (5 + 4) at 
Vall d’Hebron Hospital of Barcelona (Spain), with the approval of the Ethic Commitee of Clinic Investigation n. 
PR(AG)96/2015. PCa tissues #318 and #285 are derived from radical prostatectomies performed at the Clinical 
Hospital of the University of Chile with the approval of the Committees of Bioethics of the Faculty of Medicine 
(N° 075/2013 and N° 48/2013). Tissues were minced into small pieces by mechanical digestion, washed with 
culture medium and seeded in collagen-I/poly-d-lysin pre-coated 6-well plates. Cells were cultured in DMEM-
F12 medium supplemented with 7% heat-inactivated FBS, 2 mM l-glutamine, 100 U of penicillin/ml, 100 μg/ml 
of streptomycin, 0.1 mM non-essential amino acids, 600 µg/ml glucose, 1 mg/ml transferrin, 250 µg/ml insulin, 
100 µg/ml putrescin, 200 ng/ml sodium selenite, 1 mM hydrocortisone, 20 ng/ml EGF, 10 ng/ml βFGF, 200 ng/
ml vitamin E and 200 ng/ml vitamin A. All cells were grown in a humidiied incubator at 37 °C with 5%  CO2. 
Galiellalactone (GL) was provided by Glactone Pharma AB (Helsingborg, Sweden).͒͒͒͒͒͒͒͒͒͒͒͒͒͒
Ǥ For cell sorting, DU145 cells were harvested using a cell dissociation solution (Sigma Aldrich, 
#C5789) and incubated with antibodies to CD133-PE (#130-090-853), CD44-FITC (#130-095-195) and CD24-
APC (#130-095-954), or their corresponding isotype controls (IgG2b-PE #130–092-215, IgG1-FITC #130-092-
213, IgG1-APC #130-092-214) for 15 min at 4 °C, according to manufacturer’s instructions. All antibodies were 
from Miltenyi Biotec. Dead cells were excluded using 7-AAD (BD Pharmingen, #559925). Cell sorting was 
performed using a BD FACSAria and analyzed with BD FACSDiva sotware (BD Biosciences). Alternatively, 
 CD133+ and  CD133− cells were isolated using the CD133 MicroBead Kit (#130-100-857, Miltenyi Biotec). Sorted 
cancer stem cells (CSCs:  CD133+/CD44+ or  CD133+) and transient amplifying/committed basal cells (TA/CB: 
 CD44+/CD24+ or  CD133−) were collected in RPMI medium and plated for further experiments.
Ǥ Immunocytochemistry for pSTAT3 was conducted on DU145 parental cells and 
on sorted CSCs and TA/CB cells. Cytospins were obtained ater centrifugation at 1,200 rpm during 2 min using 
2,000 cells per sample. Expression of pSTAT3 was evaluated using the anti-pSTAT3 antibody (Tyr705, Cell Sign-
aling Technology Inc., Beverly, MA, USA) following standard avidin–biotin immunoperoxidase  procedures22. 
Stained slides were scanned using the Aperio ScanScope XT Slide Scanner system (Aperio Technologies, Vista, 
CA, USA) for bright-ield microscopy and 10 × magniication pictures were taken using the same system.
Ǥ he clonogenic ability of sorted cells was evaluated as previously  described11,44. Cells 
were seeded in 6-well collagen-coated plates (Gibco, Life Technologies) at a density of 0.8 × 103 cells/well in the 
presence of vehicle or increasing concentrations of GL (0–10 µM). Ater 24 h or 48 h medium was changed to 
complete medium and cells were let growing until colonies were spotted in the vehicle-treated group. Colonies 
were scored using the ImageJ sotware if they contained more than 50 cells (6 population doublings), usually 
between 10 and 20 days ater treatment.
Ǥ For sphere formation assays showed in Figs. 1d and 2c,d, 1 × 105 cells 
were grown in Prime-XV Tumorsphere SFM medium (Irvine Scientiic) supplemented with 2 U/ml Heparin 
(Sigma Aldrich, #H3149) and 0.5 μg/ml hydrocortisone (Sigma Aldrich, #H0135). Where indicated, cells were 
grown in the presence of vehicle or increasing concentrations of GL (0–10 µM). Cells were grown in Ultra-Low 
attachment multiwell plates (Corning) for 5–10 days, until spheres were clearly visible. Spheres in each well were 
then counted manually under the microscope and 10 × magniication pictures were taken using the same system.
For data presented in Fig. 5, spheres were generated from docetaxel-sensitive and docetaxel-resistant DU145 
cells and from primary cell lines by seeding single cells (2 × 106/dish) in 15 cm dishes pre-treated with Poly-
2-hydroxyethyl methacrylate (PolyHEMA) (Sc Quimigen), in order to inhibit cell attachment. Cells were plated 
in serum-free DMEM-F12 medium containing 2 mM l-glutamine, 100 U of penicillin/ml, 100 μg/ml of strepto-
mycin, 0.1 mM non-essential amino acids, 600 µg/ml glucose, 1 mg/ml transferrin, 250 µg/ml insulin, 100 µg/ml 
putrescin, 200 ng/ml sodium selenite, 1 mM hydrocortisone, 20 ng/ml EGF, 10 ng/ml βFGF, 200 ng/ml vitamin 
E, 200 ng/ml vitamin A and 0.4% B27 (Invitrogen). Spheres were allowed to grow for 3 days (G1), then dissoci-
ated and re-plated in the same conditions for 3 more days (G2).

Ǥ Cell viability in Fig. 2a was measured using the WST-1 assay, as 
previously  described45. Briely, 2 × 103 CSCs and TA/CB cells were plated in 96 well plates in triplicate and cells 
were allowed to adhere for 24 h. he cells were then incubated with the vehicle or with increasing concentrations 
of GL (0–10 µM) for 24 h and 48 h. WST-1 reagent (Roche Applied Science) was added to each well according 
to the manufacturer’s instructions and the absorbance was measured at a wavelength of 450 nm and 630 nm as 
a reference using ELISA plate reader.
Cell growth and cell viability in Fig. 5 and Suppl. Fig. S2 were measured by using the crystal violet assay. For 
growth curves showed in Suppl. Fig. S2, cells (1.5 × 103/well) were seeded on collagen-coated 96-well plates in 
octuplicates. For cytotoxic assays showed in Fig. 5, 5 × 103 DU145-DR cells/well or 2 × 103 primary cultures/well 
were seeded on collagen-coated 96-well plates in quintuplicate. Ater 24 h, cells were treated with vehicle (PBS) 
or with increasing concentrations of GL (0–10 µM) for 48 h. At the indicated time points cells were ixed in 4% 
formaldehyde solution, washed with PBS and stained with 0.5% crystal violet for 20 min. Crystals were then 
dissolved with 15% acetic acid and optical density was read at 595 nm.
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 ǡ     Ǧ Ǥ RNA extraction, reverse tran-
scriptase PCR and quantitative real-time PCR (qPCR) were performed as previously  described46. Briely, total 
RNA from cells or tumors was extracted using Trizol (Life technologies) and the RNeasy kit (Qiagen) accord-
ing to the manufacturer’s instructions. One to two micrograms of RNA were used for cDNA synthesis using 
random primers and the RevertAid RT kit (hermo Scientiic) or the Mooney Murine Leukemia Virus Reverse 
Transcription (M-MLV-RT) kit (Promega, Madison, USA). Real-time qPCR analysis was performed on a Strata-
gene Mx3005P system (Agilent Technologies) using Maxima SYBR Green/Rox according to the manufacturer’s 
instructions (hermo Scientiic), or with the Universal Probe Library (Roche, Basel, Switzerland) on a LightCy-
cler 480 RealTime PCR instrument (Roche). he ΔΔCt method was applied to estimate relative transcript levels. 
he relative expression of studied genes was normalized to the expression of the β-actin, TBP or IPO8 genes. he 
primers used are listed in Table 3. Values are presented as mean + SD.
 Ǥ Protein extractions, determinations of protein concentration and western blots were 
performed as previously  described47. Briely, 40  μg of total proteins were prepared in 4 × Laemli bufer and 
heated to 95 °C for 5 min prior to loading on an SDS-PAGE gel. Ater separation and transfer of the proteins to 
PVDF membranes, the membranes were blocked and probed with the following antibodies: rabbit anti-pSTAT3-
SER727 (#9134, Cell Signaling Technology, 1:1,000), rabbit anti-pSTAT3-Y705 (#76315, Abcam, 1:5,000), rabbit 
anti-tSTAT3 (#4904S, Cell Signaling Technology, 1:1,000), mouse anti-ß-Actin (clone AC-15, #A5441, Sigma-
Aldrich, 1:5,000). Ater washing, the membranes were incubated with goat anti-rabbit/mouse HRP-conjugated 
secondary antibodies (Dako). Following a second wash, the separated protein bands were visualized using the 
Immobilon Western Chemiluminescence HRP substrate (Millipore) and were imaged and analyzed using the 
ChemiDoc imaging system (Bio-Rad).
ȋȌǤ he global protein synthesis ability of parental cells and G2 
spheres was evaluated by puromycin immunodetection using the SUnSET  assay48. Cells (3 × 105) were seeded 
in 6 well plates and 24 h later were treated with 10 μg/ml puromycin for 10 min. Non-treated cells were used as 
negative control; cells treated with 10 μg/ml puromycin and 10 μg/ml cycloheximide for 10 min were used as 
positive control. Cell lysates were collected and analyzed by Western blotting as previously  described42. Antibod-
ies used were goat anti-actin (I-19) (Santa Cruz Biotechnology) and Mouse Puromycin (12D10) (Millipore).
Ǥ Immunohistochemistry (IHC) analysis was 
performed on parain embedded DU145 sub cutaneous and DU145-luc orthotopic xenograts from previous 
 studies22,23. In the DU145-luc orthotopic in vivo experiment the mice were treated intraperitoneally with vehicle 
Table 3.  he table reports the sequences (FW and RV sequence) of the primers used for quantitative real-time 
PCR (qPCR).
Gene name Primer FW (5ƍ–3ƍ) Primer RV (5ƍ–3ƍ)
STAT3 GCT TCC TGC AAG AGT CGA ATG TGT AGA AGG CGT GAT TCT TCCC 
CD133 TGG GGC TGC TGT TTA TTA TTCT TGC CAC AAA ACC ATA GAA GATG 
CD44 AGA AGG TGT GGG CAG AAG AA AAA TGC ACC ATT TCC TGA GA
CD24 CTC CTA CCC ACG CAG ATT TATTC TGG TGG CAT TAG TTG GAT TTGG 
ALDHA1 TCC TGG TTA TGG GCC TAC AG CTG GCC CTG GTG GTA GAA TA
c-myc TCA AGA GGC GAA CAC ACA AC GGC CTT TTC ATT GTT TTC CA
Mcl-1 AAG GAT GGG TTT GTG GAG TTCTT GCA AAA GCC AGC AGC ACA T
Bcl-XL TCC TTG TCT ACG CTT TCC ACG GGT CGC ATT GTG GCC TTT 
Survivin ACC TGA AAG CTT CCT CGA CA TAA CCT GCC AAT GGA ACC TC
β-actin GCT CGT CGT CGA CAA CGG CTC CAA ACA TGA TCT GGG TCA TCT TCT C
ABCB1 TGT GGG AAG AAG AGC ACA GTGG TTT ATT TCT TTG CCA TCA AGCA 
ALDH1A1 GCT CTC CAC GTG GCA TCT GCC CCA TAA CCA GGA ACA AT
CCNG2 GGG GGT TGT TTT GAT GAA AGT TTG ATC ACT GGG AGG AGA GC
CD44 CAA GCA GGA AGA AGG ATG GAT AAC CTG TGT TTG GAT TTG CAG 
CD133 GGA AAC TAA GAA GTA TGG GAG AAC A CGA TGC CAC TTT CTC ACT GAT 
KLF4 GCC GCT CCA TTA CCA AGA TCT TCC CCT CTT TGG CTT G
KLF9 CTC CGA AAA GAG GCA CAA G CGG GAG AAC TTT TTA AGG CAGT 
IPO8 CAA ATG TGG CAG CTT CTA GGT ATG CAG GAG AGG CAT CAT GT
NANOG ATG CCT CAC ACG GAG ACT GT AGG GCT GTC CTG AAT AAG CA
OCT3/4 GTG CCT GCC CTT CTA GGA AT GGC ACA AAC TCC AGG TTT TCT 
SOX2 ATG GGG TTC GGT GGT CAA GT GGA GGA AGA GGT AAC ACA GG
TBP GAA CAT CAT GGA TCA GAA CAACA ATA GGG ATT CCG GGA GTC AT
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(2% DMSO in PBS) or 5 mg/kg GL (n = 10) for 9 weeks22; in the DU145 sub cutaneous xenograt model the 
mice were treated with vehicle (1% EtOH in PBS) or 3 mg/kg GL (n = 9) for 3 weeks23. Animals were euthanized 
at the end of treatment and primary tumors were dissected, ixed in 10% formalin and embedded in parain 
for immunohistochemical staining. he Malmö-Lund Ethical Committee approved all mouse experiments and 
experimental procedures (permit n. M29-13 and M148-04). All experiments were performed in accordance with 
relevant guidelines and regulations.
For IHC analysis, tissue sections from the primary tumors were processed and analyzed to evaluate the 
expression of stemness-related genes. IHC staining was conducted as previously  described47 using the EnVi-
sion Flex kit and Autostainer Plus (Dako, Glostrup, Denmark), according to the manufacturer’s instructions. 
he following antibodies were used: anti-human CD44 (156-3C11, hermo Scientiic, CA, USA), anti-human 
ALDH1A1 (HPA002123, Sigma Aldrich). For each stained slide, 20 × magniication pictures were taken using 
the Aperio ScanScope XT Slide Scanner (Aperio Technologies, Vista, CA, USA) system for bright ield micros-
copy. he number of positive cells per section was calculated using the Image Scope sotware (Aperio). CD44 
membrane staining was quantiied using the membrane v1.1 algorithm within the Halo image analysis sotware 
(Indica Labs, Corrales, NM, USA).
 Ǥ All statistical analyses were performed using GraphPad Prism sotware (Graph-
Pad Sotware Inc., La Jolla, CA, USA), and statistical signiicance was determined using analysis of variance 
(ANOVA) or Student t test. More details regarding the speciic statistical analyses that were used for each experi-
ment are reported in the igure legends.
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